USPTO Patent Applications - Biotech (C12N)

T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems

T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems

Methods for Transgenerational Genome Editing in Plants

The USPTO published patent application US20260098272A1 for methods of transgenerational genome editing in plants. The application discloses nucleic acid constructs encoding RNA-guided nucleases under constitutive promoters combined with guide RNAs for editing plant genomes across generations. Inventors include Giane Balser, Lisa Kanizay, Ramanjot Kaur, Thomas Scott Ream, Zarir Vaghchhipawala, and Chenxi Wu. The application was filed on October 6, 2025, under application number 19350752.

Method for Increasing Recombinant Protein Expression

The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.

Multivalent Trident Aptamers for Molecular Recognition

The USPTO published patent application US20260098270A1 by McMaster University on April 9, 2026. The application covers multivalent trident aptamers comprising a branched linker molecule with 2-3 variable arms connected to a root, designed for enhanced affinity and avidity in target molecular recognition. The aptamers have applications in pharmaceutical, diagnostic, and therapeutic fields.

siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment

The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.

Selective Astrocytic MAGL Inactivation for Alzheimer's Disease Treatment

USPTO published patent application US20260098268A1 for compositions and methods treating Alzheimer's disease through selective astrocytic MAGL inactivation via AAV-mediated gene silencing. Inventors: Chu Chen, Jian Zhang. Filed September 29, 2023. The invention targets neuroinflammation reduction by selectively inactivating MAGL in astrocytes rather than globally, minimizing adverse effects from neuronal 2-AG degradation disruption.

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

Mapping and Modification of Gene Network Endophenotypes

The USPTO published patent application US20260100246A1 by Inari Agriculture Technology, Inc., disclosing a machine learning method for predicting endophenotypes of interacting partner genes. The method partitions endophenotype profiles into two sets, modifies one set to a desired level, and uses a trained ML model to predict resulting changes in the unmodified set. The invention enables targeted modification of gene networks to achieve desired agricultural traits.

M13 Phage Engineered to Capture SARS-CoV-2 Virus

M13 Phage Engineered to Capture SARS-CoV-2 Virus

Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment

USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.

Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies

USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.

Cell Behavior Control Methods Without Genetic Modification

USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.

Modified Gamma Delta T Cells for Cancer Therapy

USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.

Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation

USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.

Erythroid Lineages from Pluripotent Cells

USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.

Fusion protein complexes for epigenetic regulation, cancer treatment

USPTO published patent application US20260092267A1 by inventors Seung Ja Oh and Na Ly Tran for fusion protein complexes including transcription enhancers and dCas9 proteins for epigenetic regulation. The application covers complexes with guide RNAs (gRNAs) for inducing apoptosis of colorectal cancer cells and compensating for rhodopsin deficiency to treat ocular diseases.

CRISPR Enzymes and Systems

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

Modified GlcNAc-1-Phosphotransferase sequences, patent application

USPTO published patent application US20260092263A1 for modified, truncated GlcNAc-1-Phosphotransferase (PTase) amino acid sequences that retain phosphotransferase activity. The application, filed August 4, 2025 (Application No. 19289364), covers truncated PTase forms lacking or with modified linkers and/or lacking the C-terminal transmembrane and cytosolic domain, demonstrating retained ability to phosphorylate lysosomal or non-lysosomal target proteins.

Double Tagged Serratia Marcescens Nuclease Patent Application

USPTO published patent application US20260092265A1 for a double-tagged Serratia Marcescens Nuclease (SMN) engineered with a C-terminal Chitin Binding Domain (CBD-tag) and a 6-mer poly-histidine tag connected by a Gly-Ser linker. Inventors: Dapeng Sun, Aine Quimby, Zhenyu Zhu. Application No. 19324955 was filed September 10, 2025.

Bacteriophage structural proteins via cell-free expression system

The USPTO published patent application US20260092261A1 for multi-peptide structures comprising heterologous functional sites derived from bacteriophage structural proteins produced via cell-free expression. The application, filed by Elisabeth Falgenhauer and co-inventors Friedrich Simmel, Kilian Vogele, and Sophie von Schönberg, covers compositions and methods for universal anti-microbial applications in medicine, chemistry, biotechnology, agriculture, and food industry.

Glucosyltransferase Mutant Converting Rebaudioside D to Rebaudioside M

USPTO published patent application US20260092262A1 for Shandong Benyue Biological Technology Co., Ltd covering a glucosyltransferase mutant enzyme that catalyzes conversion of Rebaudioside D (RD) to Rebaudioside M (RM). The mutant contains specific amino acid substitutions at positions 84, 88, 126, 196, and 379 and exhibits significantly higher enzyme activity than wild-type variants. The application was filed September 26, 2025.

Cell Adhesion System for Interspecies Chimeras

USPTO published patent application US20260092259A1 by inventors Jun Wu, Emily B. Ballard, and Jia Huang for a cell adhesion system enabling formation of interspecies chimeras through engineered cells expressing antigen-binding proteins or antigens with cell membrane signaling peptides. The invention facilitates generation of organs, organoids, or tissue masses from human and non-human chimeric animals for potential transplant applications.

Low-Temperature Preservation Cabinet with Temperature Isolation for Biological Samples

USPTO published patent application US20260092260A1 by Genepoint Technologies (Shanghai) Co., Ltd. for a low-temperature preservation cabinet designed for biological samples, featuring a storage region, equipment region, and temperature isolation zone between them. The filing date was December 8, 2025, with application number 19412761.

Methods of Recellularizing Tissue Transplant for Improved Transplantability

The USPTO published patent application US20260092253A1 for methods of recellularizing an organ or tissue matrix for improved transplantability. Inventors are Doris A. Taylor and Stefan M. Kren. The application was filed December 9, 2025, under application number 19413394. This publication provides public notice of the pending patent application but does not grant any patent rights.

Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 for serotype-specific cell-based assays used in characterizing Clostridia botulinum neurotoxins. The assays utilize genetically modified cells capable of discriminating between different serotypes of clostridium neurotoxins without requiring serotype-specific neutralizing antibodies or competing heavy chains. Inventors: Ward Tucker, Francis Mark Dunning, Tim Piazza. Application No. 18920316.

ALT-803 IL-15 Soluble Fusion Molecules and Methods

The USPTO published patent application US20260092097A1 for ALT-803, a complex of interleukin-15 (IL-15) superagonist mutant and dimeric IL-15 receptor α/Fc fusion protein. The application covers compositions and methods for enhancing immune response against neoplasia (multiple myeloma, melanoma, lymphoma) or viral infections (HIV). Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han. Application filed June 25, 2025.

Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells

The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.

Pepmixes for Multiviral CTL Generation

USPTO published patent application US20260092256A1 by Baylor College of Medicine covering methods of generating CTLs (cytotoxic T lymphocytes) targeting antigens from multiple viruses. The invention uses peptide mixtures exposed to PBMCs with IL4 and IL7 expansion. Published April 2, 2026, Application No. 19020866.

Methods for Generating Hematopoietic Progenitor Cells

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

TSLP Treatment Using Oligonucleotide siRNA and ASO Compositions

The USPTO published patent application US20260091053A1 disclosing oligonucleotide compositions (siRNA and antisense oligonucleotides) targeting Thymic Stromal Lymphopoietin (TSLP) for treatment of TSLP-related diseases. The application covers methods of treating airway disorders by administering oligonucleotides specific to the long isoform of TSLP. Inventors include Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, and David Rozema. The application was filed on May 19, 2025.

MicroRNA from Rhodiola for Fibroplasia Treatment

USPTO published patent application US20260091052A1 filed by Beijing Baishihekang Pharmaceutical Technology covering microRNA derived from Rhodiola root for prevention and treatment of fibroplasia medical signs and syndromes. The application (No. 19319016) was filed September 4, 2025 and published April 2, 2026, listing five inventors including Chengyu Jiang and Jianchao Du. CPC classifications indicate pharmaceutical compositions and nucleic acid technologies.

Methods for Improving Cognitive Function Using ILC2 Cranium Implants

The USPTO published patent application US20260091063A1 by Albany Medical College covering methods to improve cognitive function by implanting activated group-2 innate lymphoid cells (ILC2) into a subject's cranium. The application also discloses methods using cytokines including IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin to treat aging-associated cognitive decline. Assignee: Albany Medical College; Inventors: Qi Yang; Application No. 19335390.

Oncolytic Herpes Virus Cancer Therapy Vectors

USPTO published patent application US20260091069A1 for an oncolytic herpes simplex virus vector with dual transcriptional and translational control for cancer therapy. The vector incorporates modified ICP27 and ICP34.5 genes under CEA promoter and miRNA-124/143 control respectively, and includes a virus-expressed cytokine cassette encoding IL-12 and IL-15/IL-15RA. Inventors include William Wei-Guo Jia, Dmitry V. Chouljenko, and six others.

AAV Gene Therapy for Hypertrophic Cardiomyopathy

USPTO published patent application US20260091139A1 for AAV gene therapy compositions targeting reduced cardiac myosin binding protein C levels in subjects with hypertrophic cardiomyopathy. The application (filed September 22, 2023, Application No. 19113698) names six inventors including Peter Cameron Colosi and Eduard Ayuso. This is a publication notice with no immediate compliance obligations.

Broad Institute Gene Editing Patent for SMA Treatment

The USPTO published patent application US20260091141A1 by Broad Institute, Inc. covering gene editing methods, systems, and compositions for treating spinal muscular atrophy (SMA). The application (No. 19288071) was filed on August 1, 2025, and made publicly available on April 2, 2026. Inventors include David R. Liu, Mandana Arbab, and Zaneta Matuszek. The application covers modified messenger RNAs and delivery methods for treating microbial infections or improving subject health.

FOXG1 Gene Therapy Patent - Viral Vectors

USPTO published patent application US20260091140A1 for gene therapy constructs and viral vectors treating FOXG1 haploinsufficiency syndrome. Invented by Sarah Elizabeth Sinnett, the application (No. 19346144) includes FOXG1 encoding nucleic acids with miRNA regulatory elements to limit overexpression in vivo.

Variants of Coagulation Factor VIII and Uses Thereof

USPTO published patent application US20260091138A1 by Seattle Children's Hospital covering FVIII (coagulation factor VIII) protein variants with an N2118Q mutation for hemophilia A treatment. The application claims variants with reduced immunogenicity, higher gene expression, increased stability, and enhanced functional activity suitable for protein replacement therapy and gene therapy applications.

Retron Gene Editing Patent for Human Cell Genome

USPTO published patent application US20260091137A1 for Retron directed gene editing technology applicable to human cell genome editing. The application, filed September 15, 2023, by inventors Brian Busser and colleagues, covers compounds, polypeptides, compositions, and nucleic acid molecules for genome editing. Key CPC classifications include gene editing enzymes and genetic constructs.

ENHO gene therapy using Adropin for heart failure

The University of Pittsburgh filed a patent application (US20260091136A1) covering gene therapy methods using Adropin encoded by the ENHO gene for preventing and treating cardiometabolic diseases, specifically heart failure with preserved ejection fraction (HFpEF). The application was published on April 2, 2026.

Epilepsy Treatment via Thalamus Bistable Opsin Gene Therapy

USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy using thalamus-administered bistable type II opsin gene therapy with light activation. The application (No. 19403102) was filed November 27, 2025, and published April 2, 2026. The invention targets drug-resistant epilepsy via optogenetic modulation of thalamic neural circuits.

Recombinant AAV Vectors for Treating Proteinopathies in CNS

The USPTO published patent application US20260091134A1 by Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors encoding Progranulin (PGRN) and/or Stathmin-2 (STMN2) for treating proteinopathies in the central nervous system. The application, filed November 26, 2025 (Application No. 19401460), includes codon-optimized coding sequences and viral particle compositions.

Rod-Derived Cone Viability Factor Fusion Protein

USPTO published patent application US20260091133A1 disclosing a fusion protein comprising rod-derived cone viability factor-S (RdCVF-S), a hydrophilic peptide, and a signal peptide. The invention covers encoding nucleic acids, viral vectors, and pharmaceutical compositions for potential treatment of ocular conditions. Inventors: Tianci LUO, Daniel LIPUT, Fong Qi LIANG. Application No. 19339969 filed September 25, 2025.

Amino acid-modified lipids enable RNA delivery via lipid nanoparticles

USPTO published patent application US20260091126A1 for amino acid-modified lipids designed for RNA delivery via lipid nanoparticles (LNPs). The application, filed September 19, 2023, by inventors Kun Cheng and Pratikkumar Vinodchandra Patel, covers siRNA, mRNA, miRNA, shRNA, and oligonucleotide delivery formulations. The technology targets oncogene silencing applications.

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Cell-Penetrating Peptides for Muscular Dystrophy Treatment

USPTO published patent application US20260091120A1 by Matthew Wood et al. covering cell-penetrating peptides with dual hydrophobic domains for treating genetic disorders, specifically Duchenne muscular dystrophy. The application (filed October 21, 2025) discloses peptide compositions and conjugates with therapeutic molecules. This is a publication of a pending application and does not yet grant enforceable patent rights.

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

ASXL1 Disruption in T Cells for Immunotherapy Enhancement

The USPTO published patent application US20260091115A1 filed by St. Jude Children's Research Hospital, Inc., covering modified immune effector cells with disrupted ASXL1 genes for enhanced immunotherapy function. The application includes claims for the modified T cells, methods of generating them, and methods for using them in adoptive cell therapy treatments for diseases.

Biallelic Knockout of CTLA4

The USPTO published patent application US20260091113A1 by inventor Rafi Emmanuel covering compositions and methods for biallelic knockout of CTLA4 using RNA guide sequences. The application includes 4,891 sequence variants (SEQ ID NOs: 1-4891) with potential therapeutic applications. Filed September 18, 2023; published April 2, 2026.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen

USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.